SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle (ORCL) is trending after reporting strong earnings that beat estimates and raising its FY27 revenue guidance, driven by explosive cloud infrastructure growth and a massive increase in Remaining Performance Obligations from AI contracts. The community is actively discussing whether these robust results, which highlight significant customer prepayments for AI capacity, will finally overcome prior concerns about the company's capital expenditures.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is actively discussed following an earnings miss and reduced fiscal guidance, fueling a steep sell-off. While some in the community highlight robust demand for drone solutions amid global conflicts and the company's ongoing contract negotiations, others express concern over valuation and acquisition integration.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending following its recent positive financial results, which reported increased North America local revenue and billings, fueling a turnaround narrative. Community discussion is sharply divided between those anticipating a short squeeze due to high short interest and its valuable SumUp stake, and skeptics who view the stock as fundamentally overvalued and manipulated.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and providing strong delivery guidance, leading to multiple analyst upgrades and fueling community excitement about a potential short squeeze and a long-awaited rebound for the EV innovator, especially with its advanced in-house chip development.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace (FLY) is trending amid intense community discussion surrounding its upcoming rocket launch, where anticipation for success clashes with frustration over repeated delays, while investors also consider its long-term potential in the burgeoning space and defense sector, including "Golden Dome" contracts.

The Beachbody Co., Inc. operates as a health and wellness company. It offers holistic health and wellness platforms. The company's product offerings include digital subscriptions, nutritional products, and connected fitness products. Digital subscriptions include Beachbody On Demand (BOD) and Openfit. The subscriptions are renewed on a monthly, quarterly, or annual basis and include unlimited access to a library of live and on-demand fitness and nutrition content. Nutritional products include Shakeology, Beachbody Performance supplements, BEACHBARs, and others. Connected fitness products include The Beachbody Bike (also known as Myx), which is equipped with a swivel touch screen that enables users to engage with content beyond the indoor cycling experience and encourages broader cross-training, incorporating resistance training and yoga for a more holistic fitness experience and healthier results. The company was founded by Carl Daikeler and Jon Congdon in 1998 and is headquartered in El Segundo, CA.

Beachbody Company Inc (The) - Ordinary Shares - Class A

BODI is trending as its recent financial results, showing positive adjusted EBITDA and projected positive cash flow, fuel speculation of a turnaround for the fitness company. This has ignited a split in the community, with some anticipating a recovery while long-term investors remain deeply wary of past dilution and management's promises.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics is trending as its March 16 PDUFA date approaches for the dry eye treatment Reproxalap, where community sentiment is sharply divided between hopes for approval following a draft label and a recent procedural extension, and concerns over prior rejections, a quiet review beyond the labeling milestone, and a key executive's departure.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil (SCO) is trending as crude oil prices decline, driven by de-escalating geopolitical tensions and global supply considerations. Despite this, community frustration is widespread as the 2x inverse ETF's gains aren't proportional to oil's drop, prompting active discussion about its volatility decay and suitability for short-term bearish plays.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is trending following its transformative $615 million acquisition of Covelya Group, immediately scaling the company into a comprehensive subsea robotics platform with expanded global capabilities in defense, offshore energy, and ocean science. The community remains highly bullish despite recent share dilution, focusing on its strategic vertical integration, crucial role in maritime security amid geopolitical tensions, and the potential for a future NASDAQ uplisting to unlock significant institutional investment.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

SIGA Technologies Inc

Investors are buzzing about SIGA Technologies following its recent Q4 earnings, with community discussions centering on the company's robust cash reserves, the likelihood of a special dividend, and the highly anticipated new BARDA contract for TPOXX, solidifying its role in biodefense amidst ongoing global health concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KALA BIO, Inc. (NASDAQ:KALA) Given Average Rating of "Hold" by Analysts

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been assigned a consensus rating of "Hold" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One...

<ul class="summary-bullets"><li>A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.</li><li>A two-stage preferred stock deal supplies up to $6 million to stabilize operations and restructure debts.</li><li>New turnaround-focused leadership was appointed as part of the recovery plan.</li></ul>Kala Bio surged 22% after hours on Tuesday after the company disclosed a rescue financing agreement that temporarily stabilizes its operations and averts a pending asset seizure by its lender. The move marks the company's reversal since September, when its eye disease therapy KPI-012 failed a Phase 2 trial, triggering a roughly 90% collapse in the stock and a wave of analyst downgrades.<h2 class="st-heading-2">Emergency Financing Steps In After Default</h2>The after-hours rally followed Kala’s filing detailing a sequence of events that began on Sept. 29, when Oxford Finance issued a notice of default under the company’s loan agreement and declared all obligations immediately due.&nbsp;On Oct. 19, Oxford informed Kala it intended to foreclose on all remaining assets,&nbsp;sweep all of the company’s cash, and&nbsp;restrict the use of funds to minimal payroll expenses necessary to execute the foreclosure. The same day, Kala terminated all remaining employees except those required to support Oxford’s process.Oxford later paused the foreclosure on Nov. 3 and allowed Kala to access $125,000 of previously swept cash to negotiate a potential transaction. On Nov.9, Kala executed a convertible loan agreement with investor David Lazar for $375,000 to fund&nbsp;the preparation of its quarterly filing and support negotiations for further investment.<h2 class="st-heading-2">Lifeline Private Placement Up To $6 Million</h2>The company then entered into a securities purchase agreement on Nov. 23 under which Lazar agreed to provide up to $6 million in a two-stage private placement of Series AA and Series AAA preferred stock. The first closing occurred on Monday, delivering $1.8 million to Kala. The second closing, for an additional $4.2 million, requires shareholder approval to increase authorized common shares and permit conversion of the preferred stock. Kala will hold the shareholder meeting before March 31, 2026. The proceeds will fund current operations, liabilities, and expenses, with $1 million of the second closing earmarked for Oxford as part of the settlement arrangement.<h2 class="st-heading-2">Settlement Restructures Obligations</h2>As part of the rescue package, Kala and unit Combangio entered into a loan settlement agreement with Oxford on Nov. 23. Oxford agreed to settle all outstanding payment obligations in exchange for a $2 million cash settlement and 1.62 million shares of common stock.&nbsp;Once Kala pays the initial $1 million and issues the settlement shares, Oxford will release control of Kala’s bank accounts, reduce the outstanding loan balance by $7 million, and waive associated interest and final payments. The company also agreed to pay Oxford 10% of future equity financing proceeds, up to $1 million, with each such payment reducing loan obligations by 3x the amount contributed.Oxford’s foreclosure efforts will formally end once the full settlement payment is completed. Kala is committed to pursuing a “material strategic alternative transaction” within one year to clear the remaining settlement balance.<h2 class="st-heading-2">Leadership Changes Accompany Restructuring</h2>As part of the financing deal, David Lazar was appointed CEO and elected to the board on Nov. 21. Lazar brings a turnaround-focused background to the role. He currently leads Custodian Ventures LLC and Activist Investing LLC, firms that specialize in turnaround situations involving distressed public companies.Todd Bazemore, the prior CEO, stepped down from the role but remains on the board. Meanwhile, chief financial officer Mary Reumuth was terminated effective immediately following the first closing, and the company also announced settlement agreements for certain former executives tied to their contractual severence rights.<h2 class="st-heading-2">Fallout From Eye Drug Trial Failure</h2>The crisis began in late September when KPI-012, a treatment for persistent corneal epithelial defect, failed to meet all primary and secondary endpoints in the Phase 2b CHASE trial. The miss contradicted the positive signals seen in the earlier Phase 1b trial and led management to terminate development of KPI-012 and its broader mesenchymal stem cell secretome platform. Analysts at Mizuho, H.C. Wainwright and LifeSci Capital downgraded the stock immediately afterward, citing the unexpected data and lack of disclosed details.&nbsp;<h2 class="st-heading-2">Stocktwits Users Cite David Lazar Upside For Kala Bio</h2>On Stocktwits, retail sentiment for Kala Bio was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/140;" src="https://news.stocktwits-cdn.com/kala_ss_png_9a4902a4d7.webp" alt="kala ss.png" width="970" height="140"><figcaption>KALA sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One bullish user said, “<a href="https://stocktwits.com/symbol/KALA">$KALA</a> 1.50 next leg. David Lazar play. new<a href="https://stocktwits.com/symbol/CETY"> $CETY</a>.”<stembedurl>https://stocktwits.com/CAPITALWHISPERER/message/637454686</stembedurl>Another user said, “Look what david Lazzar did to $opgen and find out why he make<a href="https://stocktwits.com/symbol/KALA"> $KALA</a> investors very rich if they are patient.”<stembedurl>https://stocktwits.com/Frederickquan/message/637468005</stembedurl><a href="https://stocktwits.com/symbol/KALA">Kala Bio’s stock</a> has declined 91% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio’s stock (KALA) has declined 91% so far in 2025. (Photo credit: Getty Images)

Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse

A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.

Equity

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

KALA BIO (KALA) announced on Monday that its KPI-012 failed in a mid-stage clinical trial evaluating it as a treatment for persistent corneal epithelial defect.A persistent corneal epithelial defect (PCED) is a corneal injury that fails to heal within the typical timeframe of two weeks, persisting for weeks or even months despite standard treatment. Kala’s study to evaluate the safety and efficacy of two doses of KPI-012 ophthalmic solution did not meet the primary goal of complete healing of PCED at week 8, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.kalarx.com/news-releases/news-release-details/kala-bio-announces-topline-results-chase-phase-2b-clinical-trial">said</a>. It also noted that the secondary goals in the study did not achieve statistical significance, and there was no meaningful difference between the KPI-012 treatment arm and the placebo arm in the trial.The company subsequently decided to cease clinical development of KPI-012 and stated that it is evaluating its strategic options. The firm noted that it intends to preserve cash, including by laying off some of its workforce and implementing other cost-saving measures.Kim Brazzell, Chief Medical Officer of Kala Bio, said that the company is “disappointed” to see the new study results.“KPI-012 continued to be well-tolerated and demonstrated a favorable safety profile but did not demonstrate the efficacy results that would warrant advancing the program for treatment of front-of-the-eye diseases,” he added.Shares of the company slipped 89% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALA">KALA stock</a> rose to ‘extremely bullish’ from ‘neutral’ territory over the past 24 hours, while message volume rose to ‘extremely high’ from ‘high’ levels.Following the company’s announcement, LifeSci Capital downgraded Kala Pharmaceuticals to ‘Market Perform’ from ‘Outperform’ and removed the firm's price target on the stock.Mizuho analyst Graig Suvannavejh, meanwhile, expressed disappointment that the company did not share any data details or host a call to discuss the study results, as per TheFly. &nbsp;KALA stock is down by 69% this year and by about 62% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-stock-soars-pre-market-on-securing-license-for-cancer-related-pain-management-drug/chDubC3R3J2">Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Kala Bio Stock Just Plunged 89% Today – Here’s What Happened

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures. 

Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade

The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks.com featured highlights include KALA, Graham, Arq and Hawkins

KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.

Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility

New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.

Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company announced the resignation of CEO Mark Iwicki.President Todd Bazemore has been named interim CEO, while Iwicki will remain as chair of the board.&nbsp;Iwicki, who has led Kala for nearly a decade, oversaw multiple phases of drug development.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/KALA_sentiment_and_message_volume_on_Feb_12_cdc55fd016.png" alt="KALA sentiment and message volume on Feb 12.png" width="1318" height="324"><figcaption>KALA sentiment and message volume on Feb 12 as of 2 pm ET | source: Stocktwits</figcaption></figure>Despite the steep selloff, retail traders on Stocktwits believe the market reaction is excessive, as evidenced by the 'extremely bullish' sentiment score.&nbsp;One user argued that Iwicki's departure "is the best thing possible for this company" and could signal a potential sale of the company after Kala's upcoming pipeline update.<stembedurl>https://stocktwits.com/Stmkr/message/603965500</stembedurl><stembedurl>https://stocktwits.com/Sammysums/message/603977842</stembedurl>Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects, a condition that can lead to vision loss.&nbsp;The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases, while its MSC-S platform is in preclinical studies for retinal degenerative conditions like Retinitis Pigmentosa and Stargardt Disease.At the end of 2024, Kala raised approximately $10.8 million through a private placement of common shares and Series I convertible preferred stock with institutional investors.The company is expected to report fourth-quarter earnings in March. Wall Street projects an adjusted loss per share of $2.28, down from $3.62 a year ago, on no revenue.Kala shares are down just 2.2% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction

Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $ORCL earnings Tuesday?

KALA
KALA BIO Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KALA News

KALAKALA BIO Inc